130 results on '"Zitzmann-Kolbe, Sabine"'
Search Results
2. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine
3. Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer
4. DNA repair inhibitors sensitize cells differently to high and low LET radiation
5. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models
6. Data from A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
7. Supplementary Data from A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
8. A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
9. Abstract 5043: Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer
10. Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models
11. Radiobiological effects of the alpha emitter Ra-223 on tumor cells
12. Supplementary Table S1 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
13. Figure S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
14. Supplementary Methods from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
15. Supplementary Tables from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
16. Supplementary Figure Legends and Methods from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
17. Supplementary Figures from Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
18. Investigations into the synthesis, radiofluorination and conjugation of a new [18F]fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system
19. Abstract 5440: Development of a novel PSMA-targeting small molecule-Thorium-227 conjugate for the treatment of prostate cancer
20. Abstract 3311: Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) in a hormone-independent prostate cancer model
21. Abstract 3318: PSMA-targeted thorium-227 conjugate (PSMA-TTC) inhibits tumor growth and abnormal bone changes in the intratibial LNCaP xenograft model of bone-metastatic prostate cancer
22. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine
23. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
24. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
25. Abstract 1470: Preclinical activity of the first reversible, potent and selective inhibitor of EGFR exon 20 insertions
26. Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
27. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy
28. Abstract 6318: Acquired resistance in a malignant pleural mesothelioma preclinical model after treatment with Anetumab ravtansine
29. Abstract 1776: Exploring anetumab ravtansine in a preclinical model of thymic carcinoma
30. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer
31. Radiobiological effects of α-particle radiation from Ra-223 in cancer cells
32. Targeted Alpha Therapy with PSMA-TTC: Preclinical Activity at Different Dosing Schedules and Total Antibody Doses in Prostate Cancer Xenograft Models
33. Abstract A115: Mechanisms of resistance toward the FGFR inhibitor rogaratinib in preclinical urothelial bladder cancer models
34. Abstract 1141: Preclinical analysis of biodistribution and PET imaging of a zirconium-89 labeled PSMA-targeted antibody-chelator conjugate
35. Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance
36. Abstract 3927: Radium-223 α-particle radiation: Characterization of thein vitroeffects on cancer cells in monotherapy and in combination with DNA repair inhibitors
37. Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models
38. Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
39. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
40. Abstract LB-123: Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors
41. Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models
42. Abstract 4781: Changes in intracellular signaling following chronic FGFR inhibition in urothelial bladder cancer models
43. Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents
44. Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity
45. Abstract 1079: Preclinical activity of the FGFRinhibitor BAY 1163877 alone or in combination with antihormonal therapy in breast cancer
46. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
47. First Clinical Results of (d)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
48. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression Via Attenuation of BCR-Dependent and Independent Activation of NF-Kb and AKT
49. First Clinical Results of (d)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in Patients with Non–Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
50. Zn(II)-bis(cyclen) Complexes and the Imaging of Apoptosis/Necrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.